Table 3.
Targeting Effective Analgesia in Clinics for HIV (TEACH) Study Outcomes at 12 Monthsa
| Outcome | Intervention (n = 87) | Control (n = 100) | AOR (95% CI)b |
P Value |
|---|---|---|---|---|
| Provider adherence to COT guidelines | ||||
| ≥2 urine drug tests over 12 moc | 71.0% | 19.9% | 13.38 (5.85–30.60) | <.0001 |
| ≥3 primary care visits over 12 mo | 80.2% | 76.0% | 1.33 (.63–2.84) | .45 |
| Opioid treatment agreement | 75.6% | 12.8% | 61.50 (15.30–247.20) | <.0001 |
| Provider routinely consulted prescription monitoring programd | 71.4% | 45.0% | 3.85 (.99–14.93) | .05 |
| Patient-level outcomes | ||||
| ≥1 early refill over 12 moc | 21.6% | 30.4% | 0.55 (.26–1.15) | .11 |
| No. of early refills over 12 mo, mean (SD) | 0.46 (1.00) | 0.60 (1.14) | 0.64 (.32–1.30)e | .21 |
| COMM score ≥9f | 38.7% | 39.9% | 0.78 (.33–1.88) | .58 |
| COMM score ≥13f | 27.6% | 19.4% | 1.68 (.59–4.77) | .33 |
| Discontinuation of opioid prescriptions (MEDD of 0 in the 60 d prior to visit) | 30.3% | 25.6% | 1.62 (.82–3.22) | .17 |
| Pain severity (BPI), mean (SD)f | 6.30 (2.87) | 5.76 (2.87) | 0.10 (−1.56 to 1.75)g | .91 |
| Pain interference (BPI), mean (SD)f | 5.70 (2.98) | 4.99 (3.58) | 0.30 (−1.34 to 1.95)g | .72 |
| Past 30-d opioid/stimulant used,f | 7.5% | 12.0% | 0.65 (.15–2.79) | .57 |
| Hazardous alcohol use (AUDIT score ≥8)f | 17.9% | 10.4% | 1.03 (.21–5.02) | .97 |
| HIV virologic control | ||||
| Undetectable viral load (<200 copies/mL) | 86.9% | 82.1% | 1.21 (.47–3.09) | .69 |
| CD4 count, cells/μL, mean (SD) | 568.67 (357.43) | 500.48 (316.21) | 70.25 (−46.76 to 187.25)g | .24 |
Abbreviations: AOR, adjusted odds ratio; AUDIT, Alcohol Use Disorders Identification Test; BPI, Brief Pain Inventory; CI, confidence interval; COMM, Current Opioid Misuse Measure; COT, chronic opioid therapy; HIV, human immunodeficiency virus; MEDD, Morphine Equivalent Daily Dose; SD, standard deviation.
a Table presents unadjusted proportions and means.
bAdjusted for stratification variables site (Boston vs Atlanta) and patient volume (1–2, 3–6, 7–11, and ≥12 patients).
cPrimary outcome bolded.
dUnadjusted due to small numbers.
eAdjusted incidence rate ratio.
fSubset of patients, n = 114.
gAdjusted mean difference between arms.